Shares of Senseonics Holdings (NYSE: SENS) surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring (CGM) system has received clearance from the U.S. Food and Drug Administration (FDA).

The Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need to be replaced every 10-14 days.

With a single sensor insertion, the Eversense 365 system provides people with diabetes an uninterrupted year of glucose monitoring, reducing the burden and inconvenience of frequent sensor changes. Additionally, the system offers seamless device connectivity, high accuracy, and improved discretion with on-body vibration alerts.